Danger! Genotoxicity Was A Concern For Treximet - New Migraine Headache Treatment

NEW MIGRAINE HEADACHE TREATMENT

There were cheers the world over when Pozen announced in April 15, 2008, that Treximet, their new migraine headache treatment, was approved for release by the FDA.

Treximet is a migraine headache treatment that basically combines Imitrex with Aleve. GlaxoSmithKline, which paid Pozen $35 million dollars to develope the drug, was happy because they could effectively extend their patent on Imitrex (which expired in 2008), and migraine sufferers were happy because Treximet is reported to work faster and more effectively than Imitrex alone.

Of course, experienced Imitrex users have been combining Imitrex with Aleve for years to achieve, no doubt, the same effect.

MIGRAINE HEADACHE TREATMENT MIGHT CAUSE GENOTOXICITY

But there is still reason for concern. It took years for Pozen to get through the FDA approval system and get Treximet on the market. The FDA was concerned first with the genotoxic (DNA damage) effects of the compound in 1 of 4 studies.

In addition to DNA damage, there were other concerns as well...

OTHER MIGRAINE HEADACHE TREATMENT CONCERNS

The new migraine headache treatment also raised cardiovascular concerns.

NSAIDs and triptans have always been associated with cardiovascular trouble on their own. Those suffering from cardiovascular disease are prevented from taking triptans at all, and NDAIDs are notoriously associated with potential cardiovascular troubles. Combining both drugs in one compound would naturally raise similar concerns.

IS THIS MIGRAINE HEADACHE TREATMENT WORTH THE RISK?

Many chronic pain sufferers will say yes. Fast relief to chronic pain is almost impossible to turn down.

Although rebound headaches will result from over use of this migraine headache treatment, Treximet is already a popular go-to for those seeking abortive triptans.